RUNX3 and breast carcinoma: In general, the application of formal methods to unveil the network and model the underline genetic events responsible for DNMT1-inspired TSG RUNX3 silencing along with ML approaches to predict the 2D attributes of hypomethylating compounds (targeting DNMT1) could present new computational avenues for the treatment of breast cancer requiring epigenetic therapy.